Abstract
Erectile dysfunction is defined as the inability to achieve and maintain an erection sufficient to perform satisfactory sexual intercourse. Erectile dysfunction is one of the most common sexual dysfunctions in men undergoing cancer treatment.
The cause may be neurogenic, vascular or hormonal with an accompanying psychogenic component. Cardiovascular disease, diabetes mellitus, dyslipidemia, obesity or smoking worsen the chances of restoring erectile function in oncological patients.
Men <60 years of age have a better prognosis for recovery of erectile function. We verify the severity of the disorder with a simple five-point validated questionnaire, the International Index of Erectile Function.
We also use it when monitoring the effect of the established treatment. Modern treatment of erectile dysfunction is the administration of phosphodiesterase inhibitors of the fifth type and topical or intracavernous prostaglandin E1, non-pharmacological treatment is the use of shock waves or vacuum devices, the surgical solution consists in the implantation of a penile prosthesis.
Combination therapy may better improve erectile function, especially in patients with severe ED. An oncologist can also treat uncomplicated erectile dysfunction by administering phosphodiesterase inhibitors of the fifth type.